Atropos Health Partners with Databricks to Accelerate Evidence Generation and Advance Precision Medicine in Healthcare
PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a leader in translating real-world clinical data into personalized real-world evidence (RWE) and insights, and Databricks, the Data and AI company, today announced a partnership to advance precision medicine for healthcare and life sciences organizations. By building on the Databricks Data Intelligence Platform and leveraging Delta Sharing, Atropos Health empowers clinicians and researchers to generate actionable, evidence-based insights to accelerate drug discoveries and reduce the time from symptom to treatment.
Atropos Health utilizes Delta Sharing to access and link datasets across the Atropos Evidence™ Network, the largest federated data network in healthcare with over 300M patient records, including oncology data. Delta Sharing is Databricks' open source approach that enables customers to share live data across platforms, clouds and regions with strong security and governance. The new partnership combines Atropos Health's deep expertise in real-world evidence generation with Databricks' data intelligence expertise.
"Turning data into actionable evidence rapidly and accurately will accelerate the pace of innovation in healthcare,' said Dr. Brigham Hyde, CEO and co-founder at Atropos Health. "By responsibly and compliantly linking massive data sets in healthcare, we will drive not only better outcomes for patients, but a seamless user experience for healthcare researchers and providers."
'As we continue to help healthcare and life sciences organizations unlock the power of data intelligence, we're excited to welcome Atropos Health to the Built on Databricks Partner Program. Databricks is invested in bringing the best technology solutions to market for every industry, and this includes working with partners like Atropos Health,' said Michael Sanky, VP of Healthcare & Life Sciences GTM at Databricks. 'Atropos Health exemplifies the transformative potential of building on Databricks, and it's incredible to watch its adoption among healthcare and life sciences organizations who are excited to harness the full power of their data.'
Atropos Health recently launched Nodal Patient Deidentification and Query Time Interval Encoding across the GENEVA OS™ platform for members of the Atropos Evidence Network. The addition of Nodal Deidentification to the GENEVA OS platform enables users to fill data gaps in patients longitudinal records from participating Atropos Evidence Network sources, ensuring the most robust deidentified patient records while maintaining data possession and security.
Through this partnership, Atropos Health and Databricks are unlocking new opportunities in healthcare and life sciences by providing GENEVA OS™ and the Atropos Evidence™ Network as a single solution for data and analytics, combining Atropos Health's deep expertise in RWE with Databricks' data intelligence expertise. Customers rely on Atropos Health's portfolio of evidence-generation tools through the federated installation of GENEVA OS in their internal cloud data environment.
About Atropos Health
Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence.
To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Tredence Awarded 2025 Databricks Growth Partner of the Year for the Americas at Data + AI Summit
Recognized for bridging the 'Last Mile' in AI and accelerating RoI realization and growth for enterprises in the Americas through industry-specific Data and AI solutions. SAN FRANCISCO, June 10, 2025 /PRNewswire/ -- Tredence, a global leader in data science and AI solutions, is honored to announce its recognition as the 2025 Databricks Growth Partner of the Year for the Americas. Presented at the annual Data + AI Summit, the award highlights Tredence's impactful achievements and forward-thinking innovation in driving scalable AI transformation across industries. This recognition is powered by Tredence's partnership with Databricks, which enables enterprises to accelerate value realization and drive decision intelligence at scale. Over the past year, Tredence has deepened its partnership with Databricks to help enterprises modernize their data estates, unlock real-time insights, and operationalize AI across critical business functions. Tredence and Databricks' collaboration has resulted in measurable impact for joint customers across retail, CPG, healthcare, TMT, Travel & Hospitality and industrial sectors, empowering them to move beyond experimentation and scale AI solutions that drive profitability, efficiency, and innovation. Backed by elite partner status, Tredence's investment in a robust Databricks Business Unit, coupled with a growing pool of 600+ Databricks-certified practitioners, reinforces its commitment to delivering repeatable, scalable, and outcome-focused transformations for global enterprises. "Being named the Growth Partner of the Year for the Americas is a strong validation of the trust our clients and partners place in us - and a powerful affirmation of our commitment to delivering what we call 'Beyond Possible'. We're accelerating enterprise-wide AI impact across the Americas, fueled by a sharp industry lens and bold innovation in partnership with Databricks. As we expand our footprint in the Americas, we remain committed to advancing innovation and helping clients lead with data and AI at the core of how they reimagine business at scale," said Shashank Dubey, Chief Revenue Officer, and Co-founder at Tredence. "AI's true test is in the last mile—where strategy becomes progress. That's where Tredence delivers," added Rakesh Sancheti, Chief Growth Officer at Tredence. "Winning the Growth Partner of the Year award for the Americas reaffirms our belief that sustained enterprise modernization begins when AI moves from experimentation to execution. Our partnership with Databricks has been instrumental in helping clients accelerate their modernization journeys by delivering scalable, production-ready, industry-specific solutions that drive impact at the point of decision-making." "With bold vision and strong execution, Tredence is helping enterprises move from data complexity to clarity by delivering industry-aligned solutions that scale to real-world needs. Our partnership is one rooted in shared values of innovation, customer-centric leadership, and operational excellence, and we are proud to recognize Tredence as our Growth Partner of the Year for the Americas," said Jason McIntyre, VP, Partner Development at Databricks. The Tredence's partnership with Databricks continues to shape enterprise innovation across the Americas. The joint efforts are unlocking real-world value for enterprises across industries. Retail: Realized $58M+ in RMN revenue, reduced platform licensing costs by 30-50%, increased 3-5X in time-to-insight for marketing and CX teams. Consumer Goods: Reduced platform costs by 40% across international markets through Lakehouse modernization and accelerated planning cycles by 25–35%. Healthcare: Enabled a major healthcare provider to achieve 35% faster data processing through a strategic cloud migration. Pharma: Deployed Smart Manufacturing Command Center to cut maintenance costs by 19%, boost throughput by 12%, and speed up root cause analysis by 40%. Adding to this honor, Tredence was also awarded the Databricks Retail & CPG Partner of the Year for the fourth consecutive time, reaffirming its position as the trusted AI partner to the world's leading retail and CPG enterprises. To learn more about the Tredence – Databricks partnership, visit Join us at the Data + AI Summit in San Francisco from June 9–12 at booth #664, to explore how we're helping enterprises lead with data and AI. About Tredence Tredence is a global data science and AI solutions provider focused on solving the last-mile problem in AI – the gap between insight creation and value realization. Tredence leverages deep domain expertise, data platforms and accelerators, and strategic partnerships to provide tailored, cutting-edge solutions to its clients. The company has 3,500+ employees across San Francisco Bay Area, Chicago, London, Toronto, and Bengaluru, serving top brands in Retail, CPG, Hi-tech, Telecom, Healthcare, Travel, and Industrials. For more information, visit and follow us on LinkedIn. Photo: View original content: Sign in to access your portfolio
Yahoo
44 minutes ago
- Yahoo
Tredence Wins Fourth Consecutive Databricks Retail and CPG Partner of the Year Award at Data + AI Summit
Trusted by 8 of the top 10 retailers and CPGs and recognized for driving last mile AI impact by modernizing data, industrializing GenAI, and scaling AI. SAN FRANCISCO, June 10, 2025 /PRNewswire/ -- Tredence, a global data science and AI solutions company, today announced that it has been named the Databricks Retail & CPG (RCG) Partner of the Year for the fourth consecutive year. Tredence was selected for their standout expertise in harnessing the Databricks Data Intelligence Platform and deep domain expertise to drive exceptional value for retail and CPG clients. Presented at the annual Databricks Data + AI Summit, the award celebrates Tredence's exceptional contributions to modernizing data and AI infrastructure, accelerating GenAI implementation, and scaling AI adoption across some of the world's largest retailers and consumer brands, collectively generating over $2T in global revenue. Over the past year, Tredence has demonstrated an unparalleled commitment to helping Retail and CPG enterprise organizations build data intelligence through its collaboration with Databricks, the Data and AI company. "Tredence is the AI expert driving the Data & AI strategy for 8 of the top 10 global retailers. Together with Databricks, we're helping industry leaders modernize their data foundations, enhance governance, and operationalize GenAI," said Morgan Seybert, President and Chief Business Officer of Retail at Tredence. "Backed by our unified retail data model, 150+ AI/ML accelerators, and 12+ GenAI agents, we're solving complex data science and data engineering challenges at scale." "In CPG, speed and precision drives growth. We help brands unlock growth by bridging the gap between insight and action—using Agentic AI, predictive forecasting and connected data to optimize every shelf, in every market," said Sagar Balan, Chief Business Officer of CPG at Tredence. "Our collaboration with Databricks is helping CPG leaders turn insights into immediate business impact. This is where data stops being passive and starts delivering value that compounds." In FY25, Tredence and Databricks helped leading retail and CPG enterprises drive business value across three core areas: Modernization that delivers: Unlocked $220M EBITA, $13M in labor savings, and a 10%+ improvement in forecast accuracy for a leading grocery chain in the U.S. Monetization through intelligent activation: Enabled $58M+ in retail media network revenue, reduced platform licensing costs by 30–50%, and achieved 3–5X acceleration in time-to-insight for marketing and CX teams for a major American retailer. Industrialization of AI and GenAI: Scaled enterprise-wide GenAI leading to 3X faster adoption, 30% productivity boost, 100% compliance for a leading CPG enterprise. "Tredence continues to push the boundaries of how data and AI unlock value for our joint clients in retail and CPG," said Matt Jackson, Vice President of Sales, Retail & Consumer Goods at Databricks. "Their focus on last-mile analytics impact, coupled with a powerful library of Brickbuilder Solutions, is helping RCGs move faster—from data to decision." Adding to this honor, Tredence was also awarded the Databricks Growth Partner of the Year for the Americas, reaffirming its position as the trusted Data & AI partner to leading enterprises across the region. About Tredence Tredence is a global data science and AI solutions provider focused on solving the last-mile problem in AI – the gap between insight creation and value realization. Tredence leverages deep domain expertise, data platforms and accelerators, and strategic partnerships to provide targeted, impactful solutions to its clients. The company has 3,500+ employees across San Francisco Bay Area, Chicago, London, Toronto, and Bengaluru, serving top brands in Retail, CPG, Hi-tech, Telecom, Healthcare, Travel, and Industrials. For more information, visit and follow us on LinkedIn. Photo: View original content: Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
New data from DR.CI:LABO™ at IMCAS Asia 2025 reinforces leadership in adjunctive clinical skincare for daily and post-IPL care for Asian skin
SINGAPORE, June 10, 2025 /PRNewswire/ -- Japan's clinic-born leading derma-cosmetics brand, unveiled new findings at IMCAS Asia 2025, reaffirming its position as the go-to skincare brand for Asian skin. The data demonstrated the efficacy of VC100 Essence Lotion EX and 377VC Radiance Serum in improving skin hydration, elasticity, and pigmentation when used daily and post-IPL[1] care. "At IMCAS Asia 2025, we're proud to present new clinical evidence that reflects the needs of today's consumers and supports their aesthetic and skincare choices. Our role is to provide safe, effective skincare solutions like VC100 Essence Lotion EX and 377VC Radiance Serum that can be used as daily skincare, enhance recovery and extend results of aesthetic treatments," said Dr. Sheila Chua, Board-Certified Dermatologist and Head of Medical & Safety Sciences, Skin Health & Beauty, Kenvue Asia Pacific. VC100 Essence Lotion EX: Now with clinically proven efficacy for regular daily and post-IPL care At IMCAS Asia 2025, presented new clinical data highlighting the benefits of twice-daily use of VC100 Essence Lotion EX over eight weeks on Asian skin. Powered by 100 trillion Micro-High Penetrating APPS Vitamin C, the formulation delivered visible improvements across key skin indicators including hydration, elasticity and gloss by 21.6%, 14.6%, 8.7% respectively, and reduction in hyperpigmentation by 5.9%.[2] The study also showed a significant boost in the synthesis of five different types of collagen, increased collagen density, and skin firmness. This builds on findings presented at the American Academy of Dermatology 2025, where twice daily use of VC100 Essence Lotion EX and Emulsion over a span of eight weeks showed a similar trend of improvement to IPL.[3],[4] When used in combination with IPL, hydration and elasticity improved by 25.4% and 15.5% respectively, compared to 20.8% and 10.9% with IPL alone, and hyperpigmentation reduction accelerated, with visible improvement by Week Two. 377VC Radiance Serum: A proven brightening adjunct for IPL-treated skin also shared clinical data on 377VC Radiance Serum at IMCAS. In a five-week, randomized controlled trial, participants who used the serum daily post-IPL showed a 31.88% reduction in Melasma Area and Severity Index and a 22.13% reduction in hyperpigmentation, compared to 8.92% and 8.52% in participants that only received IPL.[5] Skin image analysis further indicates reversing and reduced risk of potential re-darkening after IPL. The serum was well tolerated on treated skin in favorable state, supporting its use in post-IPL care and reaffirming its safety profile.[5] Findings presented at IMCAS from a survey of 844 dermatologists in China validated clinical approach and reinforces its clinical credibility: 83% agreed that 377VC Radiance Serum reduces melanin synthesis and improves skin brightness, Over 75% believed it enhances post-IPL outcomes and helps prevent post-inflammatory hyperpigmentation, and 99% acknowledged growing patient demand for adjunctive clinical skincare.[6] For a detailed overview of products and posters exhibited, refer to the Data and Product Fact Sheet. For more information, visit the website. About Since 1999, has pioneered the advancement of skincare solutions in collagen health. For over 25 years, is dedicated to providing skincare solutions that unlock the potential for beauty within every skin and democratize access to clinic level treatments for all. [1] Intense Pulsed Laser [2] Taichi Nishizawa et. al., "Ex-vivo and Clinical Study of an Amphiphilic Vitamin C Derivative to Enhance Dermal Collagen and Skin Gloss", IMACS Asia 2025, 6-8 June 2025, Bangkok, Thailand [3] Frequency of IPL treatment administered: 3 times every 2 weeks, over 8 weeks (IPL output: 10-13J, about 100 shots). [4] Masahiko Ando et. al., Clinical efficacy assessment of skin care formulations containing trisodium ascorbyl6-palmitate 2-phosphate (APPS) for pre-aging skin, Poster number 61671, American Academy of Dermatology Annual Meeting, 7-11 March 2025, Orlando, Florida [5] Yueying Fu et. al., "Clinical Safety and Efficacy of a Novel Topical Phenylethyl Resorcinol Formulation for Intense Pulsed Light Adjunctive Usage for Solar Lentigo and Melasma skin", IMACS Asia 2025, 6-8 June 2025, Bangkok, Thailand [6] Joleen Goh et. al., "Knowledge, Attitude, and Practice Towards the Adjunctive Perioperative Use of Phenylethyl Resorcinol with Aesthetic Treatments", IMACS Asia 2025, 6-8 June 2025, Bangkok, Thailand View original content to download multimedia: SOURCE Sign in to access your portfolio
